Roche Backs Blueprint's Precision Therapy Pralsetinib To Challenge Lilly

Paying $675m Upfront For Rights To RET Inhibitor

The collaboration between the Swiss major and Blueprint Medicines, which could be worth up to $1.7bn, should help pralsetinib provide stiff competition to Eli Lilly's RET mutation drug Retevmo.

Gears_Sunlight
Roche looks a good fit for marketing pralsetinib • Source: Shutterstock

Roche Holding AG has delved deep into precision medicine again to license Blueprint Medicines Corporation's pralsetinib, a rearranged during transfection (RET) inhibitor that has been filed for lung and thyroid cancer and has shown potential as a rival for Eli Lilly and Company's recently approved same-class therapy Retevmo.

The Swiss drugmaker is paying $675m in cash and making a $100m equity investment in Blueprint for global co-development and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.